Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC boosted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 39.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 123,115 shares of the medical equipment provider's stock after purchasing an additional 35,069 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.18% of Lantheus worth $9,885,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in LNTH. Farallon Capital Management LLC boosted its holdings in shares of Lantheus by 595.3% during the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after acquiring an additional 1,269,900 shares during the last quarter. Norges Bank purchased a new stake in shares of Lantheus during the 4th quarter valued at about $29,956,000. Swedbank AB purchased a new stake in shares of Lantheus during the 1st quarter valued at about $26,346,000. Nomura Holdings Inc. boosted its holdings in shares of Lantheus by 105.3% during the 4th quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider's stock valued at $1,282,000 after acquiring an additional 407,507 shares during the last quarter. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of Lantheus by 25.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after acquiring an additional 394,837 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Truist Financial dropped their price target on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. JMP Securities lowered their price objective on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Thursday, July 11th. B. Riley increased their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a research note on Thursday, July 25th. Finally, Mizuho increased their price objective on shares of Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $119.00.

Lantheus Stock Performance

NASDAQ LNTH traded up $1.66 on Friday, reaching $106.47. 716,911 shares of the stock were exchanged, compared to its average volume of 1,048,600. The company's 50-day simple moving average is $100.12 and its two-hundred day simple moving average is $79.58. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The firm has a market capitalization of $7.38 billion, a PE ratio of 16.25 and a beta of 0.51. The company has a current ratio of 4.68, a quick ratio of 4.55 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. During the same period last year, the business posted $1.40 EPS. The firm's revenue for the quarter was up 22.5% compared to the same quarter last year. Analysts expect that Lantheus Holdings, Inc. will post 6.46 EPS for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business's stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Lantheus news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the completion of the transaction, the chief accounting officer now directly owns 62,216 shares of the company's stock, valued at approximately $7,661,900.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,193 shares of company stock valued at $3,949,202. Corporate insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.